Clinical trials
HER2-negative clinical trials
Below are recruiting her2-negative clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07379918Recruiting
Evaluating Endopredict® test in early HR+/HER2- breast cancer
This study looks at how well the Endopredict® genomic test helps doctors decide whether chemotherapy should be added to hormone therapy for people with early-stage, HR+/HER2- breast cancer. It is for those whose standard criteria are not enough to make a clear recommendation.
ParisAges 18 years+ - NCT07366112RecruitingPhase 2
CDK4/6 inhibitor plus hormone therapy before breast cancer surgery
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75 - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT07327229RecruitingPhase 1/Phase 2
Study of ATG-022 plus pembrolizumab for stomach or GEJ cancer
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
Hefei, AnhuiAges 18 years+ - NCT07281833RecruitingPhase 3
Testing capivasertib with hormone therapy for advanced breast cancer
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
AnderlechtAges 18 years+ - NCT07227831Recruiting
TheraBionic device for advanced hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Bay City, MichiganAges 22 years+ - NCT07218432Recruiting
TheraBionic device study for hormone-positive breast cancer
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy, for women with early-stage hormone receptor-positive, HER2-negative breast cancer. It is given before surgery to see if it can help shrink the tumor.
Clarkston, MichiganAges 22 years+ - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07190443RecruitingPhase 3
Abemaciclib after local recurrence in HR+ HER2- breast cancer
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
Koto-ku, TokyoAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07180160RecruitingPhase 2
A study of QL1706 for HR-positive, HER2-negative breast cancer
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT07178340RecruitingPhase 2
Perioperative therapy for HER2-negative stomach cancer
This trial tests a treatment given before and after surgery for a rare type of stomach cancer called hepatoid adenocarcinoma. It aims to improve outcomes for patients whose tumors are HER2-negative and have not spread too far.
BeijingAges 18–75 - NCT07164976RecruitingPhase 1/Phase 2
Ribociclib for advanced HR+ HER2- breast cancer
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
NagoyaAges 18 years+ - NCT05333328RecruitingPhase 4
Test of ovarian function suppression for low-risk premenopausal node+ breast cancer
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
Seoul, KoreaAges 20–50 - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06930859Recruiting
Study of Ribociclib for HR+ HER2-negative breast cancer in Russia
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
Sochi, Russian FederationAges 18–99 - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06905301Recruiting
Study on breast cancer medication with a mobile app
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
Pskov, RussiaAges 18–90 - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new HER2-negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-negative?
- Yes. Clin2 currently lists 155 recruiting her2-negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.